|
1
|
Mulvihill NT and Foley JB: Inflammation in
acute coronary syndromes. Heart. 87:201–214. 2002.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Badimon L, Padró T and Vilahur G:
Atherosclerosis, platelets and thrombosis in acute ischaemic heart
disease. Eur Heart J Acute Cardiovasc Care. 1:60–74.
2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Crea F and Libby P: Acute coronary
syndromes: The way forward from mechanisms to precision treatment.
Circulation. 136:1155–1166. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bester J and Pretorius E: Effects of
IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot
viscoelasticity. Sci Rep. 6(32188)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ozeren A, Aydin M, Tokac M, Demircan N,
Unalacak M, Gurel A and Yazici M: Levels of serum IL-1beta, IL-2,
IL-8 and tumor necrosis factor-alpha in patients with unstable
angina pectoris. Mediators Inflamm. 12:361–365. 2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Biasucci LM, Liuzzo G, Fantuzzi G,
Caligiuri G, Rebuzzi AG, Ginnetti F, Dinarello CA and Maseri A:
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first
2 days of hospitalization in unstable angina are associated with
increased risk of in-hospital coronary events. Circulation.
99:2079–2084. 1999.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Mulcahy R, Daly L, Graham I, Hickey N,
O'Donoghue S, Owens A, Ruane P and Tobin G: Unstable angina:
Natural history and determinants of prognosis. Am J Cardiol.
48:525–528. 1981.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nanchen D, Klingenberg R, Gencer B, Räber
L, Carballo D, von Eckardstein A, Windecker S, Rodondi N, Lüscher
TF, Mach F, et al: Inflammation during acute coronary
syndromes-Risk of cardiovascular events and bleeding. Int J
Cardiol. 287:13–18. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Biasucci LM, Liuzzo G, Grillo RL,
Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G
and Maseri A: Elevated levels of C-reactive protein at discharge in
patients with unstable angina predict recurrent instability.
Circulation. 99:855–860. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Liuzzo G, Buffon A, Biasucci LM, Gallimore
JR, Caligiuri G, Vitelli A, Altamura S, Ciliberto G, Rebuzzi AG,
Crea F, et al: Enhanced inflammatory response to coronary
angioplasty in patients with severe unstable angina. Circulation.
98:2370–2376. 1998.PubMed/NCBI View Article : Google Scholar
|
|
11
|
McCarty MF, O'Keefe JH and DiNicolantonio
JJ: Pentoxifylline for vascular health: A brief review of the
literature. Open Heart. 3(e000365)2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Perego MA, Sergio G, Artale F, Giunti P
and Danese C: Haemorrheological improvement by pentoxifylline in
patients with peripheral arterial occlusive disease. Curr Med Res
Opin. 10:135–138. 1986.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Brie D, Sahebkar A, Penson PE, Dinca M,
Ursoniu S, Serban MC, Zanchetti A, Howard G, Ahmed A, Aronow WS, et
al: Effects of pentoxifylline on inflammatory markers and blood
pressure: A systematic review and meta-analysis of randomized
controlled trials. J Hypertens. 34:2318–2329. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ueno M, Ferreiro JL, Tomasello SD,
Tello-Montoliu A, Capodanno D, Seecheran N, Kodali M, Dharmashankar
K, Desai B, Charlton RK, et al: Impact of pentoxifylline on
platelet function profiles in patients with type 2 diabetes
mellitus and coronary artery disease on dual antiplatelet therapy
with aspirin and clopidogrel. JACC Cardiovasc Interv. 4:905–912.
2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Collet JP, Thiele H, Barbato E, Barthélémy
O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T,
Folliguet T, et al: ESC Scientific Document Group: 2020 ESC
Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation. Eur
Heart J. 42:1289–1367. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Neumann FJ, Sousa-Uva M, Ahlsson A,
Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V,
Head SJ, et al: 2018 ESC/EACTS Guidelines on myocardial
revascularization. Eur Heart J. 40:87–165. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fernandes JL, de Oliveira RTD, Mamoni RL,
Coelho OR, Nicolau JC, Blotta MHSL and Serrano CV Jr:
Pentoxifylline reduces pro-inflammatory and increases
anti-inflammatory activity in patients with coronary artery
disease-a randomized placebo-controlled study. Atherosclerosis.
196:434–442. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Boldt J, Brosch C, Lehmann A, Haisch G,
Lang J and Isgro F: Prophylactic use of pentoxifylline on
inflammation in elderly cardiac surgery patients. Ann Thorac Surg.
71:1524–1529. 2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mansourian S, Bina P, Fehri A, Karimi AA,
Boroumand MA and Abbasi K: Preoperative oral pentoxifylline in case
of coronary artery bypass grafting with left ventricular
dysfunction (ejection fraction equal to/less than 30%). Anatol J
Cardiol. 15:1014–1019. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Altman R, Luciardi HL, Muntaner J, Del Rio
F, Berman SG, Lopez R and Gonzalez C: Efficacy assessment of
meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute
coronary syndromes without ST-segment elevation: The Nonsteroidal
Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2)
pilot study. Circulation. 106:191–195. 2002.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Crea F and Liuzzo G: Anti-inflammatory
treatment of acute coronary syndromes: The need for precision
medicine. Eur Heart J. 37:2414–2416. 2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Choy EH, Kavanaugh AF and Jones SA: The
problem of choice: Current biologic agents and future prospects in
RA. Nat Rev Rheumatol. 9:154–163. 2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ridker PM and Lüscher TF:
Anti-inflammatory therapies for cardiovascular disease. Eur Heart
J. 35:1782–1791. 2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Morton AC, Rothman AM, Greenwood JP, Gunn
J, Chase A, Clarke B, Hall AS, Fox K, Foley C, Banya W, et al: The
effect of interleukin-1 receptor antagonist therapy on markers of
inflammation in non-ST elevation acute coronary syndromes: The
MRC-ILA Heart Study. Eur Heart J. 36:377–384. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kleveland O, Kunszt G, Bratlie M, Ueland
T, Broch K, Holte E, Michelsen AE, Bendz B, Amundsen BH, Espevik T,
et al: Effect of a single dose of the interleukin-6 receptor
antagonist tocilizumab on inflammation and troponin T release in
patients with non-ST-elevation myocardial infarction: A
double-blind, randomized, placebo-controlled phase 2 trial. Eur
Heart J. 37:2406–2413. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Deftereos S, Giannopoulos G, Angelidis C,
Alexopoulos N, Filippatos G, Papoutsidakis N, Sianos G, Goudevenos
J, Alexopoulos D, Pyrgakis V, et al: Anti-inflammatory treatment
with colchicine in acute myocardial infarction: A pilot study.
Circulation. 132:1395–1403. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Mahaffey KW, Granger CB, Nicolau JC,
Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF,
Todaro TG, et al: Effect of pexelizumab, an anti-C5 complement
antibody, as adjunctive therapy to fibrinolysis in acute myocardial
infarction: The COMPlement inhibition in myocardial infarction
treated with thromboLYtics (COMPLY) trial. Circulation.
108:1176–1183. 2003.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Granger CB, Mahaffey KW, Weaver WD,
Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau
JC, Ruzyllo W, et al: Pexelizumab, an anti-C5 complement antibody,
as adjunctive therapy to primary percutaneous coronary intervention
in acute myocardial infarction: The COMplement inhibition in
Myocardial infarction treated with Angioplasty (COMMA) trial.
Circulation. 108:1184–1190. 2003.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Armstrong PW, Mahaffey KW, Chang WC,
Weaver WD, Hochman JS, Theroux P, Rollins S, Todaro TG and Granger
CB: COMMA Investigators. Concerning the mechanism of pexelizumab's
benefit in acute myocardial infarction. Am Heart J. 151:787–790.
2006.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Testa L, Van Gaal WJ, Bhindi R,
Biondi-Zoccai GG, Abbate A, Agostoni P, Porto I, Andreotti F, Crea
F and Banning AP: Pexelizumab in ischemic heart disease: A
systematic review and meta-analysis on 15,196 patients. J Thorac
Cardiovasc Surg. 136:884–893. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Nicholls SJ, Kastelein JJ, Schwartz GG,
Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW,
Nambi V, et al: Varespladib and cardiovascular events in patients
with an acute coronary syndrome: The VISTA-16 randomized clinical
trial. JAMA. 311:252–262. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tardif JC, Kouz S, Waters DD, Bertrand OF,
Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, et al:
Efficacy and safety of low-dose colchicine after myocardial
infarction. N Engl J Med. 381:2497–2505. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tong DC, Quinn S, Nasis A, Hiew C,
Roberts-Thomson P, Adams H, Sriamareswaran R, Htun NM, Wilson W,
Stub D, et al: Colchicine in patients with acute coronary syndrome.
The Australian COPS randomized clinical trial. Circulation.
142:1890–1900. 2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Namdar H, Zohori R, Aslanabadi N and
Entezari-Maleki T: Effect of pentoxifylline in ameliorating
myocardial injury in patients with myocardial infarction undergoing
thrombolytic therapy: A pilot randomized clinical trial. J Clin
Pharmacol. 57:1338–1344. 2017.PubMed/NCBI View
Article : Google Scholar
|
